News & Updates

A wearable activity tracker used to boost physical activity has fallen short of reducing flares and improving performance or quality of life (QoL) of patients with spondyloarthritis (SpA), results of a randomized control trial have shown.

In part B* of the two-part 16-week LILAC study, the anti-BDCA2** antibody litifilimab reduced skin disease activity in individuals with cutaneous lupus erythematosus (CLE).

Ozoralizumab, when used in combination with methotrexate (MTX), appears to yield significant reductions in the signs and symptoms of rheumatoid arthritis (RA) while having an acceptable tolerability, according to data from a double-blind, parallel-group, placebo-controlled phase II/III trial.

In the 5-year follow-up of the ESCAPE trial, exercise-based physical therapy (PT) remained noninferior to arthroscopic partial meniscectomy (APM) for the treatment of symptomatic, degenerative, MRI-confirmed meniscal tears.

Consuming Jarlsberg cheese – a type of Norwegian cheese that contains long-chained vitamin K2 and DHNA* – may help fend off bone weakening, a study from Norway has shown. What’s more, it appears to do so without adversely affecting lipid levels, even extending its benefit to glycated haemoglobin levels.

Olokizumab was superior to placebo and noninferior to adalimumab in achieving ACR20 response* among patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate maintenance therapy, according to the CREDO2** study.